Sixfold Bioscience develops Mergo®, a platform that utilizes AI to enhance the delivery mechanisms for RNA therapies. This technology addresses the challenge of effectively transporting RNA molecules to target cells, improving therapeutic efficacy and patient outcomes.
Funding
$10.6M raised to dateRaised to date based on public sources. This may differ from the amount the company actually raised and is based only on what is publicly available on the internet.
+3Founders
Product
Problem
Effective delivery of RNA therapies to target cells remains a significant challenge, limiting their therapeutic potential and patient outcomes. Traditional delivery methods often struggle with stability, specificity, and efficient cellular uptake.
Solution
Sixfold Bioscience has developed Mergo®, an AI-driven platform designed to enhance the delivery of RNA therapies. Mergo® addresses the limitations of existing delivery mechanisms by improving the stability, targeting, and cellular uptake of RNA molecules. This technology aims to increase the efficacy of RNA therapeutics, leading to better patient outcomes. By leveraging AI, Mergo® optimizes the delivery process, ensuring that RNA therapies reach their intended targets with greater precision and efficiency.
Target Audience
The primary target audience includes pharmaceutical companies and research institutions focused on developing and improving RNA-based therapeutics.
Features
- AI-driven platform for optimizing RNA delivery mechanisms
- Enhanced stability of RNA molecules during transit
- Improved targeting of specific cells and tissues
- Increased cellular uptake of RNA therapies